[Specific immunotherapy using the slow alpha fraction of Dermatophagoides pteronyssinus. Efficacy; tolerance].
This open study was made on 126 patients (72 men, 54 women). Specific immunotherapy (IT) commenced in 1988 with the Dermatophagoides pteronyssinus alpha fraction (alpha -F Dpt) a new standardised, purified allergen, of better quality, but more reactive. The patient were aged between 4 and 66 years (mean 23.1 years) the subjects were young and the majority were male. Most (93.6%) showed at least respiratory symptoms (asthma, rhinitis). In about a quarter of the patients there were also dermatological and ocular symptoms. The patients were usually desensitized according to the classical technique (76.6%) we recorded semi-accelerated IT in only one case. Overall, IT with alpha-F Dpt was efficacious (54.7% O and well tolerated (74.5%). Efficacy and tolerance were better with the "accelerated" technique than the classic (respectively 73.9% against 60.6% and 86.9%). In contrast, efficacy and tolerance were not influenced by age or sex. Finally, we believe that IT has more chance of being efficacious if the initial biological values are more significant.
Sabbah
A
A
Laboratoire d'Immuno-Allergologie, CHRU, Angers.
Ascencio
M
M
Mir
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000485:Allergens / Q000627:therapeutic use*; D000818:Animals; D039741:Antigens, Dermatophagoides; D001249:Asthma / Q000209:etiology / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003231:Conjunctivitis / Q000209:etiology / Q000628:therapy; D003888:Desensitization, Immunologic / Q000009:adverse effects; D004485:Eczema / Q000209:etiology / Q000628:therapy; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008925:Mites / Q000276:immunology*; D012220:Rhinitis / Q000209:etiology / Q000628:therapy; D014581:Urticaria / Q000209:etiology / Q000628:therapy
D000485:Allergens; D039741:Antigens, Dermatophagoides
Immunothérapie spécifique par l'alpha-fraction-retard Dermatophagoides pteronyssinus. Efficacité--tolérance.